Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 13/20 | 0.49 |
| ▸ | AKR1C2 | P52895 | 13/20 | 0.49 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HCAR3 | P49019 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17259410 | 1.00 | AKR1C3 (0.49) | AKR1C3AKR1C2AKR1C1PTGS1ALDH1A1 | |
| SCHEMBL15541605 | 0.84 | AKR1C3 (0.50) | AKR1C3AKR1C2AKR1C1PTGS1ALDH1A1 | |
| SCHEMBL15541603 | 0.84 | AKR1C3 (0.50) | AKR1C3AKR1C2AKR1C1PTGS1ALDH1A1 | |
| SCHEMBL4482651 | 0.83 | VCAM1 (0.53) | AKR1C3AKR1C2AKR1C1PTGS1ALDH1A1 | |
| SCHEMBL4482654 | 0.83 | VCAM1 (0.53) | AKR1C3AKR1C2AKR1C1PTGS1ALDH1A1 | |
| SCHEMBL18458413 | 0.82 | ALDH1A1 (0.49) | AKR1C3AKR1C2PTGS1ALDH1A1CYP2D6 | |
| SCHEMBL18290903 | 0.80 | AKR1C3 (0.61) | AKR1C3AKR1C2AKR1C1ALDH1A1CYP1A2 | |
| SCHEMBL6023193 | 0.78 | AKR1C3 (0.47) | AKR1C3AKR1C2AKR1C1PTGS1ALDH1A1 | |
| SCHEMBL6023191 | 0.78 | AKR1C3 (0.47) | AKR1C3AKR1C2AKR1C1PTGS1ALDH1A1 | |
| SCHEMBL20943203 | 0.77 | AKR1C3 (0.51) | AKR1C3AKR1C2AKR1C1PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9518050-B2 | Cyclohexyl and quinuclidinyl carbamate derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activity | ALMIRALL, S.A. (ES) | 2016-12-13 | — | — | US | disclosed |
| US-20150329535-A1 | NEW CYCLOHEXYL AND QUINUCLIDINYL CARBAMATE DERIVATIVES HAVING BETA2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITY | ALMIRALL, S.A. (ES) | 2015-11-19 | — | — | US | disclosed |
| EP-0117302-B1 | PHENOTHIAZINE DERIVATIVES | THE WELLCOME FOUNDATION LIMITED (GB) | 1990-06-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150329535-A1 | NEW CYCLOHEXYL AND QUINUCLIDINYL CARBAMATE DERIVATIVES HAVING BETA2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITY | CHRM3, CHRM2, ADRB2 | AKR1C3 1320/4885AKR1C2 2066/4885AKR1C1 2570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.